Purple Biotech Ltd
PPBT
$2.99
$0.072.40%
NASDAQ
| 12/31/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -68.37% | -68.37% | -68.37% | |
| Gross Profit | -- | 68.37% | 68.37% | 68.37% | |
| SG&A Expenses | -- | -32.99% | -37.40% | -36.74% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -70.66% | -63.86% | -51.19% | |
| Operating Income | -- | 70.66% | 63.86% | 51.19% | |
| Income Before Tax | -- | 83.69% | 79.03% | 63.56% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | 83.69% | 79.03% | 63.56% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -78.48% | -74.73% | -59.79% | |
| Net Income | -- | 83.71% | 79.05% | 63.58% | |
| EBIT | -- | 70.66% | 63.86% | 51.19% | |
| EBITDA | -- | 71.18% | 64.30% | 51.53% | |
| EPS Basic | -- | 90.99% | 84.41% | 71.95% | |
| Normalized Basic EPS | -- | 89.22% | 79.18% | 79.18% | |
| EPS Diluted | -- | 91.02% | 84.45% | 72.01% | |
| Normalized Diluted EPS | -- | 89.22% | 79.18% | 79.18% | |
| Average Basic Shares Outstanding | -- | 78.98% | 62.78% | 47.31% | |
| Average Diluted Shares Outstanding | -- | 78.98% | 62.78% | 47.31% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |